Request Free Sample ×
South Korea Asthma COPD Drugs Market Research Report- Forecast to 2035 Infographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

South Korea Asthma COPD Drugs Market

ID: MRFR/Pharma/47717-HCR
200 Pages
Satyendra Maurya
Last Updated: April 06, 2026
South Korea Asthma COPD Drugs Market Research Report By Drug Class (Bronchodilators, Corticosteroids, Combination Drugs, Leukotriene Modifiers), By Route of Administration (Inhalation, Oral, Injection, Nasal), By Application (Asthma, Chronic Obstructive Pulmonary Disease, Allergic Rhinitis, Pulmonary Hypertension) and By Patient Group (Adult, Pediatric, Geriatric) - Growth & Industry Forecast 2025 To 2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

South Korea Asthma COPD Drugs Market Infographic
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Medical Device, BY Drug Class (USD Million)
      1. 4.1.1 Bronchodilators
      2. 4.1.2 Corticosteroids
      3. 4.1.3 Combination Drugs
      4. 4.1.4 Leukotriene Modifiers
    2. 4.2 Medical Device, BY Route of Administration (USD Million)
      1. 4.2.1 Inhalation
      2. 4.2.2 Oral
      3. 4.2.3 Injection
      4. 4.2.4 Nasal
    3. 4.3 Medical Device, BY Application (USD Million)
      1. 4.3.1 Asthma
      2. 4.3.2 Chronic Obstructive Pulmonary Disease
      3. 4.3.3 Allergic Rhinitis
      4. 4.3.4 Pulmonary Hypertension
    4. 4.4 Medical Device, BY Patient Group (USD Million)
      1. 4.4.1 Adult
      2. 4.4.2 Pediatric
      3. 4.4.3 Geriatric
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Medical Device
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Medical Device
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 GlaxoSmithKline (GB)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Boehringer Ingelheim (DE)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 AstraZeneca (GB)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Novartis (CH)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Teva Pharmaceutical Industries (IL)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Merck & Co. (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Sanofi (FR)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Roche (CH)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Mylan (US)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 SOUTH KOREA MARKET ANALYSIS BY DRUG CLASS
    3. 6.3 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    4. 6.4 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
    5. 6.5 SOUTH KOREA MARKET ANALYSIS BY PATIENT GROUP
    6. 6.6 KEY BUYING CRITERIA OF MEDICAL DEVICE
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF MEDICAL DEVICE
    9. 6.9 DRIVERS IMPACT ANALYSIS: MEDICAL DEVICE
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: MEDICAL DEVICE
    11. 6.11 SUPPLY / VALUE CHAIN: MEDICAL DEVICE
    12. 6.12 MEDICAL DEVICE, BY DRUG CLASS, 2024 (% SHARE)
    13. 6.13 MEDICAL DEVICE, BY DRUG CLASS, 2024 TO 2035 (USD Million)
    14. 6.14 MEDICAL DEVICE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
    15. 6.15 MEDICAL DEVICE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
    16. 6.16 MEDICAL DEVICE, BY APPLICATION, 2024 (% SHARE)
    17. 6.17 MEDICAL DEVICE, BY APPLICATION, 2024 TO 2035 (USD Million)
    18. 6.18 MEDICAL DEVICE, BY PATIENT GROUP, 2024 (% SHARE)
    19. 6.19 MEDICAL DEVICE, BY PATIENT GROUP, 2024 TO 2035 (USD Million)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 South Korea MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY DRUG CLASS, 2025-2035 (USD Million)
      2. 7.2.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
      3. 7.2.3 BY APPLICATION, 2025-2035 (USD Million)
      4. 7.2.4 BY PATIENT GROUP, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

South Korea Medical Device Market Segmentation

Medical Device By Drug Class (USD Million, 2025-2035)

  • Bronchodilators
  • Corticosteroids
  • Combination Drugs
  • Leukotriene Modifiers

Medical Device By Route of Administration (USD Million, 2025-2035)

  • Inhalation
  • Oral
  • Injection
  • Nasal

Medical Device By Application (USD Million, 2025-2035)

  • Asthma
  • Chronic Obstructive Pulmonary Disease
  • Allergic Rhinitis
  • Pulmonary Hypertension

Medical Device By Patient Group (USD Million, 2025-2035)

  • Adult
  • Pediatric
  • Geriatric

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035